Tetraphase Pharmaceuticals (Biopharma, Biotechnology) — Funding, Investors & Signals 2026

Tetraphase Pharmaceuticals

Fighting against antimicrobial resistance is at the core of our technology and our people.

Founded 2006

Watertown, United States 14 employees Grant Total: $99.04M Biopharma, Biotechnology +1

Tetraphase Pharmaceuticals is a biopharmaceutical company founded in 2006 with the slogan, "Fighting against antimicrobial resistance is at the core of our technology and our people." The company is dedicated to combating antibiotic resistance, which is described as one of the most significant threats to humanity. According to The Review on Antimicrobial Resistance, by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. The company's lead product, XERAVA, is approved for the treatment of complicated intra-abdominal infections (cIAI). Tetraphase is driven by a well-defined mission targeting antibiotic resistance, with their recent investment being a $4.00M grant from CARB-X in April 2017. Tetraphase has the focus and flexibility to explore a broad range of antibiotic solutions. With its commitment to developing new antibiotics that can overcome the challenges of drug-resistant bacteria, the company aims to ensure the availability of effective treatments in the future. Their dedication to making novel antibiotics accessible to all patients in need reflects in their passion for combating antibiotic resistance.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	••••••	1		01 Apr 2017
Venture Round	••••••	-		01 Mar 2013
Private Equity Round	••••••	1	•••• ••••	01 Jan 2012
Series C	••••••	6		01 Jun 2010
Series B	••••••	5	•••• ••••	22 Sep 2009

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

••••••

01 Apr 2017

Venture Round

••••••

01 Mar 2013

Private Equity Round

••••••

•••• ••••

01 Jan 2012

Series C

••••••

01 Jun 2010

Series B

••••••

•••• ••••

22 Sep 2009

FAQ About Tetraphase Pharmaceuticals

Fighting against antimicrobial resistance is at the core of our technology and our people.

Tetraphase Pharmaceuticals was founded in 2006.

Tetraphase Pharmaceuticals is headquartered in Watertown, United States.

Tetraphase Pharmaceuticals operates in the following industries: Biopharma, Biotechnology, Health Care.

Tetraphase Pharmaceuticals has approximately 14 employees.

Tetraphase Pharmaceuticals has completed 7 funding rounds, raising a total of $99.04M. The latest funding stage is Grant.

Top alternatives and competitors to Tetraphase Pharmaceuticals include AdjuTec Pharma AS, Phico Therapeutics Ltd., Shield Bio, Madam Therapeutics, Arrevus. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Tetraphase Pharmaceuticals and AdjuTec Pharma AS are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Tetraphase Pharmaceuticals

General Information

Track Tetraphase Pharmaceuticals

Discover More

About Tetraphase Pharmaceuticals

Funding Rounds & Investors (7)

Tetraphase Pharmaceuticals Alternatives & Competitors

FAQ About Tetraphase Pharmaceuticals

Don't just browse. Track.